Disease · MONDO_0005081

preeclampsia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. preeclampsia. Diseases, record MONDO_0005081. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005081

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: preeclampsia; Open Targets
Open Targets ID: MONDO_0005081; Open Targets
Other names: EPH - Edema, proteinuria and hypertension of pregnancy, EPH - Oedema, proteinuria and hypertension of pregnancy, EPH Complex, EPH Gestosis, EPH Toxemia, EPH Toxemias, Edema Proteinuria Hypertension Gestosis, Gestational hypertension, Gestational hypertension (disorder), Gestosis, EPH, Gestosis, Edema-Proteinuria-Hypertension, Gestosis, Hypertension-Edema-Proteinuria, Gestosis, Proteinuria-Edema-Hypertension, Hypertension Edema Proteinuria Gestosis, PE - Pre-eclampsia, PET - Pre-eclamptic toxaemia, PET - Pre-eclamptic toxemia, PREGN TOXEMIAS, Pre Eclampsia, Pre-eclampsia (disorder), Pre-eclampsia NOS, Pre-eclampsia NOS (disorder), Pre-eclampsia, unspecified, Pre-eclamptic NOS, Pregnancy Toxemia, Pregnancy Toxemias, Pregnancy associated hypertension, Pregnancy-induced hypertension (disorder), Proteinuria Edema Hypertension Gestosis, Toxaemia NOS, Toxaemia of pregnancy, Toxaemia of pregnancy, NOS, Toxemia, Toxemia NOS, Toxemia NOS (disorder), Toxemia of Pregnancy, Toxemia of pregnancy (disorder), Toxemia of pregnancy, NOS, Toxemia, EPH, Toxemia, Pregnancy, Toxemias, EPH, Toxemias, Pregnancy, hypertension induced by pregnancy, hypertension of preg., hypertension of pregnancy NOS, hypertension of pregnancy NOS (disorder), pre-eclamptic toxaemia, pre-eclamptic toxemia, preeclampsia/eclampsia, pregnancy toxaemia, proteinuric hypertension of pregnancy; Open Targets
Disease Ontology: DOID:10591; Disease Ontology
MeSH: D011225; MeSH
NCI Thesaurus: C85021; NCI Thesaurus
Orphanet: ORPHA:275555; Orphanet
Highest stage of its drugs: Approval, for 8 of its 84 drugs, from DailyMed; Open Targets

Drugs84

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
MAGNESIUM SULFATE	CHEMBL3989857	Small molecule	Approval	DailyMed	24	22	22	Drugs and targets
SPIRONOLACTONE	CHEMBL1393	Small molecule	Approval	DailyMed	3	1	1	Drugs and targets
HYDROCHLOROTHIAZIDE	CHEMBL435	Small molecule	Approval	DailyMed	6	0	0	Drugs and targets
TRIAMTERENE	CHEMBL585	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
CHLOROTHIAZIDE	CHEMBL842	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
CHLORTHALIDONE	CHEMBL1055	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
INDAPAMIDE	CHEMBL406	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
METOLAZONE	CHEMBL878	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
LABETALOL	CHEMBL429	Small molecule	Phase 3	ClinicalTrials.gov	9	9	9	Drugs and targets
NIFEDIPINE	CHEMBL193	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets

1 to 10 of 84

See all 84 drugs

Targets131

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRA2A	Adrenergic receptor	7	Adrenergic receptor agonist; Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-2 agonist; Adrenergic receptor antagonist	Phase 3	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor	7	Adrenergic receptor agonist; Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-2 agonist; Adrenergic receptor antagonist	Phase 3	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor	7	Adrenergic receptor agonist; Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-2 agonist; Adrenergic receptor antagonist	Phase 3	https://conductscience.org/library/genes/152	Drugs and targets
ADRA1A	Adrenergic receptor	6	Adrenergic receptor agonist; Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-1 agonist; Adrenergic receptor antagonist	Phase 3	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor	6	Adrenergic receptor agonist; Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-1 agonist; Adrenergic receptor antagonist	Phase 3	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor	6	Adrenergic receptor agonist; Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-1 agonist; Adrenergic receptor antagonist	Phase 3	https://conductscience.org/library/genes/146	Drugs and targets
PTGS2	Cyclooxygenase	5	Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor	Phase 2/3	https://conductscience.org/library/genes/5743	Drugs and targets
SERPINC1	Antithrombin-III	5	Antithrombin-III activator	Phase 3	https://conductscience.org/library/genes/462	Drugs and targets
SLC12A3	Solute carrier family 12 member 3	5	Thiazide-sensitive sodium-chloride cotransporter inhibitor	Approval	https://conductscience.org/library/genes/6559	Drugs and targets
ADRB1	Adrenergic receptor	4	Adrenergic receptor agonist; Adrenergic receptor antagonist; Beta-1 adrenergic receptor antagonist	Phase 3	https://conductscience.org/library/genes/153	Drugs and targets

1 to 10 of 131

See all 131 targets

Trials100

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 6 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02059135	Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia	Phase 3	120	2017-08-09	Preeclampsia	ANTITHROMBIN III HUMAN	Its record names the disease	ClinicalTrials.gov
NCT00458003	Phenylephrine in Spinal Anesthesia in Preeclamptic Patients	Not applicable	110	2022-06-02	Preeclampsia, Hypotension	EPHEDRINE, PHENYLEPHRINE	Its record names the disease	ClinicalTrials.gov
NCT02835339	Magnesium Sulfate in Obese Preeclamptics	Phase 4	66	2020-05-13	Preeclampsia	MAGNESIUM SULFATE	Its record names the disease	ClinicalTrials.gov
NCT02296931	Assessment of a Syringe Pump to Pre-eclamptic Women in a Low-resource Hospital	Phase 1/2	34	2016-10-05	Pre-eclampsia	MAGNESIUM SULFATE	Its record names the disease	ClinicalTrials.gov
NCT03482440	Angiotensin II and Chronic Inflammation in Persistent Microvascular Dysfunction Following Preeclampsia	Early phase 1	24	2025-06-03	Preeclampsia	SALSALATE	Its record names the disease	ClinicalTrials.gov
NCT03419364	Study of Nicotinamide in Early Onset Preeclampsia	Phase 2	23	2022-09-08	Pre-Eclampsia, Pregnancy Related	NIACINAMIDE	Its record names the disease	ClinicalTrials.gov
NCT04632589	Losartan for Improved Vascular Endothelial Function After Preeclampsia	Early phase 1	11	2025-07-10	Preeclampsia Postpartum	LOSARTAN POTASSIUM	Its record names the disease	ClinicalTrials.gov
NCT02213094	Phase I Study of Nicotinamide for Early Onset Preeclampsia	Phase 1	10	2018-11-02	Pregnancy Induced Hypertension, Superimposed Preeclampsia, Hypertension	NIACINAMIDE	Its record names the disease	ClinicalTrials.gov
NCT01566630	Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia	Phase 2	3	2015-11-05	Pre-eclampsia	SERELAXIN	Its record names the disease	ClinicalTrials.gov
NCT04725812	Complement Regulation to Undo Systemic Harm in Preeclampsia	Phase 2	2	2023-11-29	Preeclampsia, Severe Preeclampsia, Eculizumab, HELLP, HELLP Syndrome, HELLP Syndrome Second Trimester, Pregnancy Related, AHUS, PNH, Complement Regulatory Factor Defect, Complement Abnormality, HELLP Syndrome Third Trimester	ECULIZUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 100

See all 100 trials

Comparisons in its trials10

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Salsalate vs Placebo: deaths from any cause	0 of 23	0 of 23	46	NCT03482440	Trial comparisons
Salsalate vs Placebo: serious adverse events	0 of 23	0 of 23	46	NCT03482440	Trial comparisons
MgSO4 4g Load, 1g/hr Infusion vs MgSO4 6g Load, 2g/hr Infusion: deaths from any cause	0 of 18	0 of 19	37	NCT02835339	Trial comparisons
MgSO4 4g Load, 1g/hr Infusion vs MgSO4 6g Load, 2g/hr Infusion: serious adverse events	0 of 18	0 of 19	37	NCT02835339	Trial comparisons
Healthy Adults vs Pre-eclamptic Pregnant Women: serious adverse events	0 of 10	0 of 24	34	NCT02296931	Trial comparisons
Losartan vs Placebo: deaths from any cause	0 of 11	0 of 11	22	NCT04632589	Trial comparisons
Losartan vs Placebo: serious adverse events	0 of 11	0 of 11	22	NCT04632589	Trial comparisons
Nicotinamide 500 mg vs Nicotinamide 1000 mg: deaths from any cause	0 of 5	0 of 5	10	NCT02213094	Trial comparisons
Nicotinamide 500 mg vs Nicotinamide 1000 mg: Number of Participants With Adverse Events	2 of 5	0 of 5	10	NCT02213094	Trial comparisons
Nicotinamide 500 mg vs Nicotinamide 1000 mg: serious adverse events	2 of 5	0 of 5	10	NCT02213094	Trial comparisons

Papers from its trials82

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39638148	RESULT	1	PubMed
27756248	RESULT	1	PubMed
27400005	RESULT	1	PubMed
26429521	RESULT	1	PubMed
26384980	RESULT	1	PubMed
25305214	RESULT	1	PubMed
25280034	RESULT	1	PubMed
24917564	RESULT	1	PubMed
24818590	RESULT	1	PubMed
23798922	RESULT	1	PubMed

1 to 10 of 82

See all 82 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005081

GET https://conductscience.org/api/diseases/v1/MONDO_0005081/drugs?page=2

API reference For AI assistants